First Lab-in-a-Briefcase to Boost Global Early Diagnosis of Cancer
|
By LabMedica International staff writers Posted on 18 Nov 2015 |

Image: The 4 main components of the newly developed “lab-in-a-briefcase.” (1) Disposable multiple syringe aspirator (MSA) devices, each of which can perform 10 replicate ELISA tests on each of the 8 samples. (2) Customized microwell plates preloaded with reagents that interface with the MSA. (3) Portable USB-powered film scanner for colorimetric signal quantification. (4) Portable computer for real-time data analysis (Photo courtesy of Barbosa AI et al., 2015, and the journal Lab on a Chip.)
To help boost early cancer detection rates worldwide, scientists have developed an all-in-one portable mini-laboratory for point-of-care cancer screening, rapid detection, and monitoring. The prototype successfully tested for prostate cancer, and can operate at even at high temperatures often found in remote areas without air-conditioned clinics.
An estimated 70% of the world’s cancer deaths occur in Africa, Asia, and Central and South America. The lab-in-a-briefcase, believed to be a first-of-its-kind, was developed by a team from Loughborough University (Leicestershire, UK) and Capillary Film Technology, Ltd. (West Sussex,UK), led by Dr. Nuno Reis, lecturer in chemical engineering, Loughborough University.
One of the system’s remarkable features is the use whole blood without the need for sample preparation, which has been a challenging task for settings outside of a central laboratory. This also provides improved safety by minimizing the handling of blood samples from patients that may have infectious diseases.
The compact system, a complete miniaturized ELISA platform, comprises of 4 main components: a manually driven multi-syringe aspirator capable of performing up to 80 simultaneous tests from whole blood samples; microwell ELISA plates pre-loaded with assay reagents; a portable USB-powered film scanner to image test-strips; and a portable computer for real-time data analysis.
The easy-to-use, semi-automated system requires only one operator with minimal training to conduct the test within 15 minutes – with no need for additional equipment or instruments.
A new affordable, disposable microfluidic test-strip—comprising of tiny capillary tubes about the width of a human hair—is used specifically for quick measurement of different cancer biomarkers in a whole blood sample. This technology, which operates like a pregnancy test, has already been used successfully in a separate study led by Dr. Reis that detected prostate cancer with the help of a smartphone camera. The new, lab-in-a-briefcase study also focused on detecting prostate cancer (by testing for the PSA [prostate-specific antigen] biomarker); however the microfluidic test-strip is versatile enough to measure several cancer biomarkers simultaneously from a single sample.
“Our lab-in-a-briefcase is both inexpensive and simple to use; it means that high-precision diagnostic kits, complete with clinical laboratory equipment, can be made accessible to remote populations, and this is what makes it a truly life-changing concept for the screening and monitoring of different types of cancer,” said
Dr. Reis, “This portable lab can really make a difference, boosting levels of cancer detection in developing countries where ordinarily people would not have such easy access to early diagnostics. I envisage that our lab-in-a-briefcase could also be developed further in the future to allow for rapid testing of infectious diseases and allergens.”
The study, by Barbosa AI et al, was published in June, 2015, in the journal Lab on a Chip.
Related Links:
Loughborough University
Capillary Film Technology
An estimated 70% of the world’s cancer deaths occur in Africa, Asia, and Central and South America. The lab-in-a-briefcase, believed to be a first-of-its-kind, was developed by a team from Loughborough University (Leicestershire, UK) and Capillary Film Technology, Ltd. (West Sussex,UK), led by Dr. Nuno Reis, lecturer in chemical engineering, Loughborough University.
One of the system’s remarkable features is the use whole blood without the need for sample preparation, which has been a challenging task for settings outside of a central laboratory. This also provides improved safety by minimizing the handling of blood samples from patients that may have infectious diseases.
The compact system, a complete miniaturized ELISA platform, comprises of 4 main components: a manually driven multi-syringe aspirator capable of performing up to 80 simultaneous tests from whole blood samples; microwell ELISA plates pre-loaded with assay reagents; a portable USB-powered film scanner to image test-strips; and a portable computer for real-time data analysis.
The easy-to-use, semi-automated system requires only one operator with minimal training to conduct the test within 15 minutes – with no need for additional equipment or instruments.
A new affordable, disposable microfluidic test-strip—comprising of tiny capillary tubes about the width of a human hair—is used specifically for quick measurement of different cancer biomarkers in a whole blood sample. This technology, which operates like a pregnancy test, has already been used successfully in a separate study led by Dr. Reis that detected prostate cancer with the help of a smartphone camera. The new, lab-in-a-briefcase study also focused on detecting prostate cancer (by testing for the PSA [prostate-specific antigen] biomarker); however the microfluidic test-strip is versatile enough to measure several cancer biomarkers simultaneously from a single sample.
“Our lab-in-a-briefcase is both inexpensive and simple to use; it means that high-precision diagnostic kits, complete with clinical laboratory equipment, can be made accessible to remote populations, and this is what makes it a truly life-changing concept for the screening and monitoring of different types of cancer,” said
Dr. Reis, “This portable lab can really make a difference, boosting levels of cancer detection in developing countries where ordinarily people would not have such easy access to early diagnostics. I envisage that our lab-in-a-briefcase could also be developed further in the future to allow for rapid testing of infectious diseases and allergens.”
The study, by Barbosa AI et al, was published in June, 2015, in the journal Lab on a Chip.
Related Links:
Loughborough University
Capillary Film Technology
Latest Technology News
- Noninvasive Sputum Test Detects Early Lung Cancer
- New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
- Rapid Biosensor Detects Drug Sensitivity in Breast Tumors
- Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
- Online Tool Supports Family Screening for Inherited Cancer Risk
- Portable Breath Sensor Detects Pneumonia Biomarkers in Minutes
- New Electronic Pipette Enhances Workflows with Touchscreen Control
- AI Model Outperforms Clinicians in Rare Disease Detection
- AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
- Blood Test “Clocks” Predict Start of Alzheimer’s Symptoms
- AI-Powered Biomarker Predicts Liver Cancer Risk
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Channels
Clinical Chemistry
view channelNext Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
Clinical laboratories continue to face staffing shortages, limited space, and growing test volumes that pressure chemistry and electrolyte workflows. Maintaining rapid turnaround times increasingly depends... Read more
Blood Metabolite Test Detects Early Cognitive Decline
Timely identification of individuals at risk of dementia remains difficult because symptoms commonly appear only after significant neurodegeneration. Accessible screening tools that flag subtle cognitive... Read moreMolecular Diagnostics
view channel
Noninvasive Urine Test Predicts Recurrence After BCG in Bladder Cancer
Bladder cancer is among the most common malignancies in the United States and frequently recurs even when diagnosed at the non‑muscle invasive stage (NMIBC). After transurethral resection, many patients... Read more
Mesothelioma in Younger Adults Linked to Genetic Risk Factors
Mesothelioma is a rare malignancy of the pleura, historically linked to occupational asbestos exposure and most often diagnosed in older men. About 3,300 people are diagnosed each year in the United States,... Read moreHematology
view channel
New Platelet Function Assay Enables Monitoring of Antiplatelet Therapy
Monitoring response to antiplatelet therapy remains challenging for many clinical laboratories. Aggregation-based assays and cartridge systems often require specialized personnel, dedicated instruments,... Read more
Open Multi-Omics Platform Identifies Prognostic Subtypes in Blood Cancers
Blood cancers encompass diverse entities whose biology and clinical behavior are best understood through integrative analyses across large cohorts. However, multi‑omic datasets and outcomes information... Read moreImmunology
view channelCombined Screening Approach Identifies Early Leprosy Cases
Leprosy remains a significant public health concern, with more than 200,000 new cases reported globally each year and early disease often escaping routine laboratory detection. In its initial phase, bacterial... Read more
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
Cost-Effective Sampling and Sequencing Workflow Identifies ICU Infection Hotspots
Intensive care units face persistent threats from hospital-acquired infections, increasingly driven by drug-resistant bacteria. Rapidly pinpointing environmental reservoirs and transmission hotspots remains... Read more
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read morePathology
view channel
AI Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
Small cell lung cancer often presents at an extensive stage and progresses rapidly, leaving little time to tailor first-line therapy. Clinicians currently lack biomarkers to guide which patients will benefit... Read more
Tumor-Specific Biomarker Predicts Neoadjuvant Immunotherapy Response in Gastric Cancer
Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer mortality worldwide, with China bearing nearly half of the global burden. Only a subset of patients benefit from... Read moreIndustry
view channel
GRAIL Partners with Epic to Integrate Multi-Cancer Test into EHR
GRAIL’s Galleri multi-cancer early detection (MCED) test is being integrated into Epic’s electronic health record (EHR) platform through Epic Aura. The collaboration is designed to let clinicians at interested... Read moreGlobal Partnership Aims to Streamline NGS Tumor Profiling in Oncology Trials
CellCarta and Pillar Biosciences announced a global, multi-year strategic partnership on April 2, 2026 to broaden access to operationally streamlined next-generation sequencing (NGS) tumor profiling for... Read more







